Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Benzimidazolone-based selective σ2 receptor ligands: Synthesis and pharmacological evaluation.

Intagliata S, Alsharif WF, Mesangeau C, Fazio N, Seminerio M, Xu YT, Matsumoto RR, McCurdy CR.

Eur J Med Chem. 2019 Mar 1;165:250-257. doi: 10.1016/j.ejmech.2019.01.019. Epub 2019 Jan 9.

PMID:
30685525
2.

Synthesis and Structural Elucidation of a Pyranomorphinan Opioid and in Vitro Studies.

Ansari MI, Healy JR, Hom K, Deschamps JR, Matsumoto RR, Coop A.

Org Lett. 2018 May 18;20(10):2984-2987. doi: 10.1021/acs.orglett.8b01025. Epub 2018 May 8.

PMID:
29737176
3.

Deuterated (d6)-dextromethorphan elicits antidepressant-like effects in mice.

Nguyen L, Scandinaro AL, Matsumoto RR.

Pharmacol Biochem Behav. 2017 Oct;161:30-37. doi: 10.1016/j.pbb.2017.09.005. Epub 2017 Sep 12.

PMID:
28916283
4.

Relationship Between Grit with Academic Performance and Attainment of Postgraduate Training in Pharmacy Students.

Palisoc AJL, Matsumoto RR, Ho J, Perry PJ, Tang TT, Ip EJ.

Am J Pharm Educ. 2017 May;81(4):67. doi: 10.5688/ajpe81467.

5.

Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection.

Nguyen L, Lucke-Wold BP, Mookerjee S, Kaushal N, Matsumoto RR.

Adv Exp Med Biol. 2017;964:133-152. doi: 10.1007/978-3-319-50174-1_10. Review.

6.

Single low-dose lipopolysaccharide preconditioning: neuroprotective against axonal injury and modulates glial cells.

Turner RC, Naser ZJ, Lucke-Wold BP, Logsdon AF, Vangilder RL, Matsumoto RR, Huber JD, Rosen CL.

Neuroimmunol Neuroinflamm. 2017 Jan;4:6-15. doi: 10.20517/2347-8659.2016.40. Epub 2017 Jan 20.

7.

Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.

Healy JR, Bezawada P, Griggs NW, Devereaux AL, Matsumoto RR, Traynor JR, Coop A, Cunningham CW.

Bioorg Med Chem Lett. 2017 Feb 1;27(3):666-669. doi: 10.1016/j.bmcl.2016.11.057. Epub 2016 Nov 22.

8.

Behavioral and biochemical effects of ketamine and dextromethorphan relative to its antidepressant-like effects in Swiss Webster mice.

Nguyen L, Lucke-Wold BP, Logsdon AF, Scandinaro AL, Huber JD, Matsumoto RR.

Neuroreport. 2016 Sep 28;27(14):1004-11. doi: 10.1097/WNR.0000000000000646.

9.

Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use.

Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR.

Pharmacol Ther. 2016 Aug;164:170-82. doi: 10.1016/j.pharmthera.2016.04.010. Epub 2016 Apr 29. Review.

10.

Salubrinal reduces oxidative stress, neuroinflammation and impulsive-like behavior in a rodent model of traumatic brain injury.

Logsdon AF, Lucke-Wold BP, Nguyen L, Matsumoto RR, Turner RC, Rosen CL, Huber JD.

Brain Res. 2016 Jul 15;1643:140-51. doi: 10.1016/j.brainres.2016.04.063. Epub 2016 Apr 27.

11.

Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders.

Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR.

Pharmacol Ther. 2016 Mar;159:1-22. doi: 10.1016/j.pharmthera.2016.01.016. Epub 2016 Jan 28. Review.

PMID:
26826604
12.

Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review.

Nguyen L, Marshalek PJ, Weaver CB, Cramer KJ, Pollard SE, Matsumoto RR.

Neuropsychiatr Dis Treat. 2015 Oct 14;11:2667-73. doi: 10.2147/NDT.S88569. eCollection 2015.

13.

Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice.

Nguyen L, Matsumoto RR.

Behav Brain Res. 2015 Dec 15;295:26-34. doi: 10.1016/j.bbr.2015.03.024. Epub 2015 Mar 21.

PMID:
25804358
14.

Role of sigma-1 receptors in neurodegenerative diseases.

Nguyen L, Lucke-Wold BP, Mookerjee SA, Cavendish JZ, Robson MJ, Scandinaro AL, Matsumoto RR.

J Pharmacol Sci. 2015 Jan;127(1):17-29. doi: 10.1016/j.jphs.2014.12.005. Epub 2014 Dec 11. Review.

15.

Altering endoplasmic reticulum stress in a model of blast-induced traumatic brain injury controls cellular fate and ameliorates neuropsychiatric symptoms.

Logsdon AF, Turner RC, Lucke-Wold BP, Robson MJ, Naser ZJ, Smith KE, Matsumoto RR, Huber JD, Rosen CL.

Front Cell Neurosci. 2014 Dec 10;8:421. doi: 10.3389/fncel.2014.00421. eCollection 2014.

16.

Sigma receptors as potential therapeutic targets for neuroprotection.

Nguyen L, Kaushal N, Robson MJ, Matsumoto RR.

Eur J Pharmacol. 2014 Nov 15;743:42-7. doi: 10.1016/j.ejphar.2014.09.022. Epub 2014 Sep 27. Review.

17.

Evaluation of an improved sustained-release buprenorphine formulation for use in mice.

Healy JR, Tonkin JL, Kamarec SR, Saludes MA, Ibrahim SY, Matsumoto RR, Wimsatt JH.

Am J Vet Res. 2014 Jul;75(7):619-25. doi: 10.2460/ajvr.75.7.619.

PMID:
24959727
18.

Methamphetamine-induced toxicity: an updated review on issues related to hyperthermia.

Matsumoto RR, Seminerio MJ, Turner RC, Robson MJ, Nguyen L, Miller DB, O'Callaghan JP.

Pharmacol Ther. 2014 Oct;144(1):28-40. doi: 10.1016/j.pharmthera.2014.05.001. Epub 2014 May 14. Review.

19.

Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan.

Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR.

PLoS One. 2014 Feb 28;9(2):e89985. doi: 10.1371/journal.pone.0089985. eCollection 2014.

20.

SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation.

Robson MJ, Turner RC, Naser ZJ, McCurdy CR, O'Callaghan JP, Huber JD, Matsumoto RR.

Exp Neurol. 2014 Apr;254:180-9. doi: 10.1016/j.expneurol.2014.01.020. Epub 2014 Feb 6.

21.

Sigma (σ) receptors as potential therapeutic targets to mitigate psychostimulant effects.

Matsumoto RR, Nguyen L, Kaushal N, Robson MJ.

Adv Pharmacol. 2014;69:323-86. doi: 10.1016/B978-0-12-420118-7.00009-3. Review.

PMID:
24484982
22.

Elucidating the severity of preclinical traumatic brain injury models: a role for functional assessment?

Turner RC, VanGilder RL, Naser ZJ, Lucke-Wold BP, Bailes JE, Matsumoto RR, Huber JD, Rosen CL.

Neurosurgery. 2014 Apr;74(4):382-94; discussion 394. doi: 10.1227/NEU.0000000000000292.

23.

Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro.

Kaushal N, Robson MJ, Rosen A, McCurdy CR, Matsumoto RR.

Eur J Pharmacol. 2014 Feb 5;724:193-203. doi: 10.1016/j.ejphar.2013.12.039. Epub 2013 Dec 28.

24.

Chlorophenylpiperazine analogues as high affinity dopamine transporter ligands.

Motel WC, Healy JR, Viard E, Pouw B, Martin K, Matsumoto RR, Coop A.

Bioorg Med Chem Lett. 2013 Dec 15;23(24):6920-6922. doi: 10.1016/j.bmcl.2013.09.038. Epub 2013 Oct 15.

25.

Effect of ring-constrained phenylpropyloxyethylamines on sigma receptors.

Stavitskaya L, Seminerio MJ, Healy JR, Noorbakhsh B, Matsumoto RR, Coop A.

Bioorg Med Chem. 2013 Sep 1;21(17):4923-7. doi: 10.1016/j.bmc.2013.06.068. Epub 2013 Jul 11.

PMID:
23896610
26.

Modeling clinically relevant blast parameters based on scaling principles produces functional & histological deficits in rats.

Turner RC, Naser ZJ, Logsdon AF, DiPasquale KH, Jackson GJ, Robson MJ, Gettens RT, Matsumoto RR, Huber JD, Rosen CL.

Exp Neurol. 2013 Oct;248:520-9. doi: 10.1016/j.expneurol.2013.07.008. Epub 2013 Jul 20.

PMID:
23876514
27.

Structure activity relationship study of benzo[d]thiazol-2(3H)one based σ receptor ligands.

Bhat R, Fishback JA, Matsumoto RR, Poupaert JH, McCurdy CR.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):5011-3. doi: 10.1016/j.bmcl.2013.06.032. Epub 2013 Jun 29.

28.

σ Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation.

Robson MJ, Seminerio MJ, McCurdy CR, Coop A, Matsumoto RR.

Pharmacol Rep. 2013;65(2):343-9.

29.

Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.

Healy JR, Bezawada P, Shim J, Jones JW, Kane MA, MacKerell AD Jr, Coop A, Matsumoto RR.

ACS Chem Neurosci. 2013 Sep 18;4(9):1256-66. doi: 10.1021/cn4000428. Epub 2013 Jun 11.

30.

SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation.

Robson MJ, Turner RC, Naser ZJ, McCurdy CR, Huber JD, Matsumoto RR.

Exp Neurol. 2013 Sep;247:134-42. doi: 10.1016/j.expneurol.2013.04.009. Epub 2013 Apr 28.

31.

In vitro evaluation of guanidine analogs as sigma receptor ligands for potential anti-stroke therapeutics.

Behensky AA, Cortes-Salva M, Seminerio MJ, Matsumoto RR, Antilla JC, Cuevas J.

J Pharmacol Exp Ther. 2013 Jan;344(1):155-66. doi: 10.1124/jpet.112.199513. Epub 2012 Oct 12.

32.

The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice.

Seminerio MJ, Hansen R, Kaushal N, Zhang HT, McCurdy CR, Matsumoto RR.

Int J Neuropsychopharmacol. 2013 Jun;16(5):1033-44. doi: 10.1017/S1461145712000831. Epub 2012 Aug 29.

PMID:
22932447
33.

Pharmacological evaluation of SN79, a sigma (σ) receptor ligand, against methamphetamine-induced neurotoxicity in vivo.

Kaushal N, Seminerio MJ, Robson MJ, McCurdy CR, Matsumoto RR.

Eur Neuropsychopharmacol. 2013 Aug;23(8):960-71. doi: 10.1016/j.euroneuro.2012.08.005. Epub 2012 Aug 24.

34.

A 96-well filtration method for radioligand binding analysis of σ receptor ligands.

Fishback JA, Rosen A, Bhat R, McCurdy CR, Matsumoto RR.

J Pharm Biomed Anal. 2012 Dec;71:157-61. doi: 10.1016/j.jpba.2012.07.023. Epub 2012 Aug 9.

35.

New positron emission tomography (PET) radioligand for imaging σ-1 receptors in living subjects.

James ML, Shen B, Zavaleta CL, Nielsen CH, Mesangeau C, Vuppala PK, Chan C, Avery BA, Fishback JA, Matsumoto RR, Gambhir SS, McCurdy CR, Chin FT.

J Med Chem. 2012 Oct 11;55(19):8272-8282. doi: 10.1021/jm300371c. Epub 2012 Sep 20.

36.

Sigma receptor antagonists attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1β mRNA expression in the hypothalamus.

Seminerio MJ, Robson MJ, McCurdy CR, Matsumoto RR.

Eur J Pharmacol. 2012 Sep 15;691(1-3):103-9. doi: 10.1016/j.ejphar.2012.07.029. Epub 2012 Jul 20.

37.

Effects of aging on behavioral assessment performance: implications for clinically relevant models of neurological disease.

Turner RC, Seminerio MJ, Naser ZJ, Ford JN, Martin SJ, Matsumoto RR, Rosen CL, Huber JD.

J Neurosurg. 2012 Sep;117(3):629-37. doi: 10.3171/2012.5.JNS112224. Epub 2012 Jun 29.

PMID:
22746378
38.

Deconstructing 14-phenylpropyloxymetopon: minimal requirements for binding to mu opioid receptors.

Stavitskaya L, Shim J, Healy JR, Matsumoto RR, MacKerell AD Jr, Coop A.

Bioorg Med Chem. 2012 Jul 15;20(14):4556-63. doi: 10.1016/j.bmc.2012.05.006. Epub 2012 May 11.

39.

Nature against depression.

El-Alfy AT, Abourashed EA, Matsumoto RR.

Curr Med Chem. 2012;19(14):2229-41. Review.

PMID:
22414105
40.

Sigma-1 receptors: potential targets for the treatment of substance abuse.

Robson MJ, Noorbakhsh B, Seminerio MJ, Matsumoto RR.

Curr Pharm Des. 2012;18(7):902-19. Review.

PMID:
22288407
41.

CM156, a sigma receptor ligand, reverses cocaine-induced place conditioning and transcriptional responses in the brain.

Xu YT, Robson MJ, Szeszel-Fedorowicz W, Patel D, Rooney R, McCurdy CR, Matsumoto RR.

Pharmacol Biochem Behav. 2012 Mar;101(1):174-80. doi: 10.1016/j.pbb.2011.12.016. Epub 2011 Dec 30.

42.

Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine.

Seminerio MJ, Robson MJ, Abdelazeem AH, Mesangeau C, Jamalapuram S, Avery BA, McCurdy CR, Matsumoto RR.

AAPS J. 2012 Mar;14(1):43-51. doi: 10.1208/s12248-011-9311-8. Epub 2011 Dec 20.

43.

AC927, a σ receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells.

Kaushal N, Elliott M, Robson MJ, Iyer AK, Rojanasakul Y, Coop A, Matsumoto RR.

Mol Pharmacol. 2012 Mar;81(3):299-308. doi: 10.1124/mol.111.074120. Epub 2011 Nov 18.

44.

Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo.

Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR.

Eur Neuropsychopharmacol. 2012 Apr;22(4):308-17. doi: 10.1016/j.euroneuro.2011.08.002. Epub 2011 Sep 10.

PMID:
21911285
45.

Synthesis and pharmacological evaluation of indole-based sigma receptor ligands.

Mésangeau C, Amata E, Alsharif W, Seminerio MJ, Robson MJ, Matsumoto RR, Poupaert JH, McCurdy CR.

Eur J Med Chem. 2011 Oct;46(10):5154-61. doi: 10.1016/j.ejmech.2011.08.031. Epub 2011 Aug 29.

46.

Role of sigma receptors in methamphetamine-induced neurotoxicity.

Kaushal N, Matsumoto RR.

Curr Neuropharmacol. 2011 Mar;9(1):54-7. doi: 10.2174/157015911795016930.

47.

CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice.

Kaushal N, Seminerio MJ, Shaikh J, Medina MA, Mesangeau C, Wilson LL, McCurdy CR, Matsumoto RR.

Neuropharmacology. 2011 Oct-Nov;61(5-6):992-1000. doi: 10.1016/j.neuropharm.2011.06.028. Epub 2011 Jul 7.

48.

Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents.

Kaushal N, Robson MJ, Vinnakota H, Narayanan S, Avery BA, McCurdy CR, Matsumoto RR.

AAPS J. 2011 Sep;13(3):336-46. doi: 10.1208/s12248-011-9274-9. Epub 2011 Apr 15.

49.

Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine.

Matsumoto RR, Li SM, Katz JL, Fantegrossi WE, Coop A.

Drug Alcohol Depend. 2011 Oct 1;118(1):40-7. doi: 10.1016/j.drugalcdep.2011.02.017. Epub 2011 Mar 21.

50.

Sigma (σ) receptor ligand, AC927 (N-phenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice.

Seminerio MJ, Kaushal N, Shaikh J, Huber JD, Coop A, Matsumoto RR.

Pharmacol Biochem Behav. 2011 Mar;98(1):12-20. doi: 10.1016/j.pbb.2010.11.023. Epub 2010 Dec 2.

Supplemental Content

Loading ...
Support Center